Pages that link to "Q39665939"
Jump to navigation
Jump to search
The following pages link to A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. (Q39665939):
Displaying 50 items.
- ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models (Q24628845) (← links)
- Current and novel therapeutic molecules and targets in Alzheimer's disease (Q26798231) (← links)
- Alzheimer's therapeutics: translation of preclinical science to clinical drug development (Q26829267) (← links)
- Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines (Q26858963) (← links)
- Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model (Q28550356) (← links)
- Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis (Q30442608) (← links)
- APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). (Q30455082) (← links)
- Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease (Q33707872) (← links)
- CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition. (Q33735544) (← links)
- Obovatol improves cognitive functions in animal models for Alzheimer's disease. (Q34243963) (← links)
- L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases β-amyloid peptide production in HEK293-APPswe cells (Q34355809) (← links)
- A peptide binding to the β-site of APP improves spatial memory and attenuates Aβ burden in Alzheimer's disease transgenic mice (Q34469761) (← links)
- Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. (Q34584517) (← links)
- Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. (Q34624551) (← links)
- Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents (Q34950867) (← links)
- A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice (Q35426661) (← links)
- Drug development for Alzheimer's disease: recent progress (Q35545974) (← links)
- Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression (Q35551497) (← links)
- Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo (Q35683767) (← links)
- Developing β-secretase inhibitors for treatment of Alzheimer's disease (Q35746998) (← links)
- A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice (Q35903525) (← links)
- BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. (Q35945545) (← links)
- Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages (Q36113733) (← links)
- Alzheimer's β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid (Q36246858) (← links)
- The A673T mutation in the amyloid precursor protein reduces the production of β-amyloid protein from its β-carboxyl terminal fragment in cells (Q36247247) (← links)
- Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease (Q36869427) (← links)
- Therapeutic Potential and Anti-Amyloidosis Mechanisms of Tert-Butylhydroquinone for Alzheimer's Disease (Q36940911) (← links)
- Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis (Q37013605) (← links)
- Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model (Q37041542) (← links)
- Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease (Q37065293) (← links)
- Substrate ectodomain is critical for substrate preference and inhibition of γ-secretase. (Q37305181) (← links)
- Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. (Q37556990) (← links)
- Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors (Q37866692) (← links)
- The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease (Q37884646) (← links)
- Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions (Q37979824) (← links)
- The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond (Q37987919) (← links)
- Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity (Q38026045) (← links)
- Disease modifying drugs targeting β-amyloid (Q38027791) (← links)
- Animal models of Alzheimer disease (Q38045853) (← links)
- Advances in the identification of β-secretase inhibitors (Q38097074) (← links)
- BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status (Q38120669) (← links)
- Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. (Q38127470) (← links)
- Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. (Q38230384) (← links)
- New directions for protease inhibitors directed drug discovery (Q38638651) (← links)
- A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis. (Q38905278) (← links)
- Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig. (Q39087660) (← links)
- Generation of gene-targeted mice using embryonic stem cells derived from a transgenic mouse model of Alzheimer's disease (Q39282763) (← links)
- AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. (Q42710724) (← links)
- Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on Aβ peptide levels and impaired learning behavior in aged rats (Q42904574) (← links)
- Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools (Q46109982) (← links)